We have a long-standing commitment to address global health crises, such as Ebola, which builds on our history of redefining treatment paradigms. We are committed to bringing forward transformational vaccines to help overcome the threat of some of the world’s most life-threatening infectious diseases.
In response to the Ebola outbreak in West Africa in 2014–16, Janssen, with the support of global partners, committed to accelerate the development of a preventive Ebola vaccine regimen.As of November 2020, more than 110,000 people have received Janssen’s European Commission-approved Ebola vaccine in clinical studies and vaccination initiatives, including in the DRC and Rwanda during the 2018–20 outbreak.
We strive to be partners of choice in collaborations and actively work with governments, industry, advocacy and academia to develop and deliver vaccines that serve the needs of diverse populations worldwide. As a result of our collaborative efforts, we were able to help those most at need, with the ultimate goal of preventing outbreaks before they start.
Despite being preventable and curable, TB is the leading cause of death from a single infectious agent and one of the top ten causes of death worldwide.
In 2019, approximately 1.4 million people died from TB – more than HIV/AIDS and malaria combined. In Europe, TB incidence is among the lowest in the world – there was an estimated 26,000 deaths in 2016 from TB in Europe – but the region’s burden of new and retreated cases of multidrug-resistant tuberculosis (MDR-TB) is among the highest in the world.
For nearly 20 years, Janssen has been supporting global efforts to end TB and combat antimicrobial resistance – both in our laboratories and on the ground in countries impacted by TB and MDR-TB.